Migraine is the third-most prevalent disease in the world and affects 
approximately 39 million individuals in the United States alone. Migraine occurs 
in nearly 1 in 7 individuals between 15 and 49 years of age and is 3 times more 
frequent in women than in men. The Food and Drug Administration (FDA) recently 
approved 3 new humanized monoclonal antibodies that target calcitonin 
gene-related peptide (CGRP): erenumab, fremanezumab, and galcanezumab. The 
agents either bind to the CGRP receptor (erenumab) or bind to the CGRP ligand 
(fremanezumab and galcanezumab) and block its binding to the receptor. All 3 
products are indicated for preventative treatment of episodic or chronic 
migraine in adults. The available studies to date document that these agents 
reduce migraine attacks. The CGRP monoclonal antibodies offer patients new 
options once they have exhausted other treatments.